Journal
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Volume 12, Issue -, Pages 2687-2693Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/COPD.S145253
Keywords
infections; prevention; treatment; COPD; exacerbations
Categories
Funding
- Boehringer Ingelheim
- Menarini
- Vivisol
- Astra Zeneca
- Guidotti-Malesci
- Grifols
- Almirall
- AstraZeneca
- Biofutura
- Chiesi Farmaceutici
- GlaxoSmithKline
- Menarini Group
- Mundipharma
- Novartis
- Zambon
- Bayer
- consultancies for Insmed
- Grigols
- Polyphor
- Pfizer
- Boehringer
- Lallemand
- Verona Pharma
- Farmaceutici
- Chiesi
- Dompe
- GSK
- Guidotti
- Teva
Ask authors/readers for more resources
Acute exacerbations are a leading cause of worsening COPD in terms of lung - function decline, quality of life, and survival. They also have a relevant economic burden on the health care system. Determining the risk factors for acute exacerbation and early relapse could be a crucial element for a better management of COPD patients. This review analyzes the current knowledge and underlines the main risk factors for recurrent acute exacerbations. Comprehensive evaluation of COPD patients during stable phase and exacerbation could contribute to prevent treatment failure and relapses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available